According to a study published in JAMA Network, Elinzanetant, a non-hormonal treatment, has demonstrated an 80% success rate in reducing menopause symptoms.
This clinical trial focused on alleviating symptoms like hot flashes and night sweats, which are common during menopause. The results indicated that 80% of the women who took elinzanetant experienced significant relief, offering a promising alternative to traditional hormone replacement therapy (HRT).
The study involved women between the ages of 40 and 65 who were experiencing moderate to severe menopause symptoms [1]. Participants were randomly assigned to receive either 120 mg of elinzanetant or a placebo daily for 12 weeks.
By the end of the study, women who took elinzanetant reported an 80% reduction in symptoms, particularly in the frequency and severity of hot flashes. In contrast, the placebo group reported a much smaller reduction in symptoms.
Elinzanetant targets neurokinin-1, -2 and -3 receptors, which regulate body temperature and other functions disrupted during menopause [2]. By blocking these receptors, elinzanetant helps reduce the occurrence and intensity of hot flashes and night sweats without needing hormonal intervention.
This non-hormonal approach is particularly significant for women who cannot use hormone replacement therapy due to the risks associated with breast cancer, cardiovascular issues or other health concerns. The safety profile of elinzanetant was also noted in the study, with mild side effects such as headaches, nausea and fatigue being the most commonly reported.
These side effects were generally well-tolerated by participants and did not lead to significant withdrawals from the study.
The results of this study suggest that elinzanetant could be a breakthrough in the management of menopause symptoms, especially for women seeking alternatives to hormone therapy. The high success rate in reducing symptoms highlights the potential for elinzanetant to improve the quality of life for many women during menopause.
Further research is needed to evaluate the long-term effects and benefits of elinzanetant. Still, this study marks a promising step forward in women’s health, providing a viable option for those who need or prefer a non-hormonal treatment for menopause symptoms.
[1] JAMA Network. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause
[2] Bayer US. Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause
